ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
ACTU | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1751 RIVER RUN, 76107 FORT WORTH
- Website:
- https://actuatetherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hard-to-treat cancers with high unmet medical needs. The company's lead drug candidate is elraglusib, a novel Glycogen Synthase Kinase-3 (GSK-3) inhibitor. This agent targets multiple molecular pathways involved in promoting tumor growth and resistance to conventional cancer drugs. Elraglusib is also being investigated for its role as a mediator of anti-tumor immunity through the inhibition of immune checkpoints and the regulation of immune cell function. Actuate aims to develop therapies that slow, stop, or shrink tumors while minimizing adverse effects for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ACTUATE THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ACTUATE THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ACTUATE THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
